News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Gamida Cell Ltd.-Teva Pharmaceutical Industries Limited (TEVA) Joint Venture Receives FDA Fast Track Designation for StemEx(R) for Leukemia and Lymphoma



6/21/2010 7:21:35 AM

JERUSALEM--(BUSINESS WIRE)--Gamida Cell announced today that the Gamida Cell-Teva Joint Venture has received an FDA Fast Track Designation for StemEx, in development as an alternative to a bone marrow transplant for patients with blood cancers such as leukemia and lymphoma.

Read at BioSpace.com


comments powered by Disqus
   
Lymphoma
Leukemia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES